OakChart

Tarsus Pharmaceuticals Inc

TARSHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 1:00 PM ET

76.45+2.62 (3.55%)
2026-11-11 19:00 CET
Market cap
3,640.23 USD m
Revenue, TTM
682.20 USD m
Net income, TTM
-702.23 USD m
Free cash flow, TTM
32.44 USD m
EPS diluted, TTM
-15.18
P/E
-
Compare

Price

TARS against its 20, 50 and 200-day averages
2050200miss
60.0070.0080.0090.001.5M3.0MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TARSclose 76.4520-day 71.2350-day 75.02200-day 67.8376.4552w high52w low

16.5% under the 52-week high of 91.53 on 4 Sep 2026. 52-week low 53.89 on 15 Jul 2026. Last 15 sessions, 17.6% high to low

Profile

TARS
52-week range, 60% of the way up
53.8991.53

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

IndexRUT
Employees370
IPOOct 16, 2020
Beta0.34
ATR, 14d3.71
Rel volume0.36
Short float13.00%
Insider own5.38%
Inst own93.81%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.77B
Enterprise Value3.55B
Income-702.23M
Sales682.20M
Book/sh2.11
Cash/sh6.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees370
IPOOct 16, 2020

Ratios

P/E-
Forward P/E171.76
PEG-
P/S5.53
P/B36.23
P/C12.17
P/FCF116.20
EV/EBITDA-
EV/Sales5.20
Quick Ratio1.94
Current Ratio1.96
Debt/Eq0.85
LT Debt/Eq0.85
Option/ShortYes / Yes

Earnings

EPS (ttm)-15.18
EPS next Y0.45
EPS next Q-0.28
EPS this Y-878.20%
EPS next Y102.86%
EPS next 5Y-
EPS past 3/5Y14.26% -3.80%
Sales past 3/5Y159.54% -
EPS Y/Y TTM-654.07%
Sales Y/Y TTM86.34%
EPS Q/Q-4773.76%
Sales Q/Q63.92%
EarningsNov 03 AMC
EPS/Sales Surpr.-886.84% 3.59%

Ownership

Insider Own5.38%
Insider Trans-3.37%
Inst Own93.81%
Inst Trans1.34%
ROA-135.04%
ROE-319.84%
ROIC-364.42%
Gross Margin93.21%
Oper. Margin-9.61%
Profit Margin-102.93%
SMA207.33%
SMA501.91%
SMA20012.71%
Trades-

Technical

Shs Outstand49.30M
Shs Float46.65M
Short Float13.00%
Short Ratio6.97
Short Interest6.07M
52W High91.53 -16.48%
52W Low53.89 41.86%
Volatility7.33% 5.46%
ATR (14)3.71
RSI (14)58.80
Beta0.34
Rel Volume0.36
Avg Volume870.14K
Volume177,902

Performance

Perf Week10.68%
Perf Month7.95%
Perf Quarter10.99%
Perf Half Y18.23%
Perf YTD-6.63%
Perf Year1.07%
Perf 3Y337.61%
Perf 5Y178.10%
Perf 10Y-
Recom1.09
Target Price102.70
Prev Close73.83
Price76.45
Change %3.55%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Sep 24, 2026ResumedGGoldmanBuy$116+51.7%
Sep 16, 2026ResumedBBarclaysOverweight$110+43.9%
Apr 24, 2026ResumedOOppenheimerOutperform$105 → $98+28.2%
Dec 09, 2025InitiatedBBarclaysOverweight$100+30.8%
Nov 20, 2025InitiatedMMizuhoOutperform$100+30.8%
Jun 02, 2025ResumedOOppenheimerOutperform$75-1.9%
May 27, 2025ResumedHH.C. WainwrightBuy$72-5.8%
Nov 20, 2023InitiatedGGoldmanNeutral$19-75.1%
Jul 18, 2023InitiatedWWilliam BlairOutperform$44-42.4%
May 18, 2023InitiatedGGuggenheimBuy

Peers

Mkt cap
TickerCompanyMkt cap
OCULOcular Therapeutix Inc1.45B
LENZLENZ Therapeutics Inc132.28M
BLCOBausch + Lomb Corp7.61B
OCSOculis Holding AG483.06M
HROWHarrow Inc1.10B
ARQTArcutis Biotherapeutics Inc3.58B
ALCAlcon Inc34.64B
ALDXAldeyra Therapeutics Inc37.75M
EYPTEyePoint Inc32.01M
GKOSGlaukos Corp14.53B

Insider trading

latest 14 of 89
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
LINK WILLIAM J PHDDirectorSep 15 '26Sale78.3812,500979,74494,487Sep 17 04:22 PM
WILLIAM J LINKDIRECTORSep 15 '26Proposed Sale78.3812,500979,745Sep 15 04:51 PM
Azamian Bobak R.President/CEO and Board ChairSep 04 '26Sale90.5610,000905,600827,991Sep 09 04:14 PM
Lin Elizabeth YeuChief Medical OfficerSep 04 '26Sale87.5010,773942,6352,547Sep 09 04:13 PM
Lin Elizabeth YeuChief Medical OfficerSep 04 '26Sale87.503,180278,2501,590Sep 09 04:13 PM
Neervannan SeshadriChief Operating OfficerSep 04 '26Sale85.004,564387,94078,532Sep 09 04:12 PM
BOBAK AZAMIANOFFICERSep 04 '26Proposed Sale90.5610,000905,587Sep 04 05:23 PM
Lin Elizabeth YeuMember of immediate family ofSep 04 '26Proposed Sale87.503,180278,250Sep 04 04:03 PM
Lin Elizabeth YeuOfficerSep 04 '26Proposed Sale87.5010,773942,635Sep 04 03:59 PM
Neervannan SeshadriOfficerSep 04 '26Proposed Sale85.004,564387,940Sep 04 03:36 PM
Lin Elizabeth YeuChief Medical OfficerSep 02 '26Sale80.005,387430,96013,320Sep 03 04:29 PM
Lin Elizabeth YeuChief Medical OfficerSep 01 '26Sale73.864,601339,83018,707Sep 03 04:29 PM
Lin Elizabeth YeuChief Medical OfficerSep 02 '26Sale80.001,590127,2004,770Sep 03 04:29 PM
Lin Elizabeth YeuMember of immediate family ofSep 02 '26Proposed Sale80.001,590127,200Sep 02 04:31 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
FBTFirst Trust NYSE Arca Biotechnology Index FundAUM: 3.03B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
PJPInvesco Pharmaceuticals ETFAUM: 603.92M
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IHEiShares U.S. Pharmaceuticals ETFAUM: 1.72B

News

latest 14 of 206
  • Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Tarsus Beats As XDEMVY Guidance Rises Again, But A $632 Million Pipeline Bet Reshapes The Balance Sheet (Earnings Whispers)
  • Tarsus Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Tarsus Must Show Xtemvi Can Outrun Its Pricier Retina Ambitions In Q3 (Earnings Whispers)
  • Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 (GlobeNewswire)
  • Loading…
  • Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer (GlobeNewswire)
  • Lisata adds biopharma finance veteran Jeffrey Farrow to board (Proactive)
  • Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting (GlobeNewswire)
  • Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care (GlobeNewswire) +9.10%
  • Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.76%
  • Tarsus joins Stargardt race to market with $800m Alkeus takeover (Pharmaceutical Technology)
  • Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... (GuruFocus.com) +6.59%
  • Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M (BioPharma Dive)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-14.400-1.459-14.400194.57187.839
2026Q22026-08-06-0.430-0.192-0.428173.91169.658
2026Q12026-05-06-0.160-0.400-0.162162.05149.69
2025Q42026-02-23-0.200-0.093-0.196151.67144.578
2025Q32025-11-04-0.300-0.349-0.295118.7115.237
2025Q22025-08-06-0.480-0.379-0.480102.6695.687
2025Q12025-05-01-0.640-0.730-0.63878.3472.437
2024Q42025-02-25-0.600-0.743-0.59966.4158.809
2024Q32024-11-13-0.610-0.940-0.61048.1243.188
2024Q22024-08-08-0.880-0.923-0.88040.8132.339
2024Q12024-05-08-1.010-1.181-1.01227.6117.898
2023Q42024-02-27-1.310-1.372-1.31213.085.479
2023Q32023-11-09-1.280-1.350-1.2781.870.407
2023Q22023-08-10-1.170-1.079-1.1720.000.007
2023Q12023-05-09-0.880-0.956-0.8762.503.335
2022Q42023-03-13-0.460-0.668-0.50915.2710.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-4.320-2.324-1.3190.000.00
2021FY-0.670-0.573-0.67357.0349.07
2022FY-2.520-2.363-2.52225.8225.86
2023FY-4.620-4.791-4.62517.459.70
2024FY-3.070-3.218-3.073182.95175.34
2025FY-1.590-1.429-1.570451.36444.1
2026FY--15.553--741.28
2027FY-0.445--941.31
2028FY-3.277--1,163
2029FY-7.330--1,403
2030FY-10.956--1,641

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-04981210.77203.16214
2026Q4S2026-11-03950205.78191.61222.5
2026Q4S2026-10-28950205.78191.61222.5
2026Q4S2026-10-27950205.78191.61222.5
2026Q4S2026-10-20940204.8191.61222.5
2026Q4S2026-10-14960201.4191.61210
2026Q4S2026-10-09950200.29191.61207.07
2026Q4S2026-09-23950199.82191.61205.8
2026Q4S2026-09-03841196.29183202.87
2026Q4S2026-08-11741195.76183202.87
2026Q4S2026-08-10741195.45183202.3
2026Q4S2026-08-06750198.84191.61206.7
2026Q4S2026-08-05820195.8180.08206.7
2026Q4S2026-07-30820195.83180.08207

Estimate history

EPS, annual-0.068-0.23-1.319-0.673-2.522-4.625-3.073-1.59-15.1825
Period20182019202020212022202320242025TTM
EPS, quarterly-0.61-0.599-0.638-0.48-0.295-0.196-0.162-0.428-14.397
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00057.02725.81617.447182.953451.36682.2
Period20182019202020212022202320242025TTM
Sales, quarterly48.11866.40878.335102.66118.697151.668162.054173.912194.569
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual19.50920.32320.32320.69926.72734.21138.3542.55449.303
Period20182019202020212022202320242025MRQ
Shares, quarterly38.19638.3541.99642.21142.44842.55443.02143.27149.303
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue682.20451.36182.9517.4525.8257.030.000.000.00
Cost of Goods Sold Incl. D&A46.3330.6812.831.590.952.080.250.070.00
Gross Profit635.87420.68170.1315.8524.8654.95-0.25-0.07-0.00
Selling, General and Administrative Excl. Other701.42491.64290.70159.0187.5767.1126.744.221.35
Research and Development115.5964.3253.3950.3142.6241.7118.813.160.90
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-65.54-70.97-120.57-143.16-62.71-12.16-26.98-4.30-1.35
Interest Expense8.688.947.853.352.200.000.000.04-
Unusual Expense630.560.002.15-0.380.771.580.010.330.00
Net Income Before Taxes-690.46-64.36-115.55-135.89-62.09-13.77-26.81-4.67-1.32
Income Taxes11.772.060.000.00-0.000.060.000.000.00
Consolidated Net Income-702.23-66.42-115.55-135.89-62.09-13.83-26.81-4.67-1.32
Net Income From Continuing Operations-702.23-66.42-115.55-135.89-62.09-13.83-26.81-4.67-1.32
Net Income-702.23-66.42-115.55-135.89-62.09-13.83-26.81-4.67-1.32
EPS (Recurring)-5.62-1.59-3.03-4.63-2.50-0.62-1.32-0.22-0.07
EPS (Basic, Before Extraordinaries)-15.18-1.59-3.07-4.62-2.52-0.67-1.32-0.23-0.07
EPS (Diluted)-15.18-1.59-3.07-4.62-2.52-0.67-1.32-0.23-0.07
EBITDA-62.64-69.15-119.34-142.28-61.92-11.55-26.74-4.22-1.35
Non-Operating Income (Expense)14.3315.5415.0110.233.58-0.040.190.000.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense47.0132.9627.8219.8310.636.170.610.010.01
Price To Sales Ratio5.357.5811.3834.1013.988.11---
Gross Margin93.2193.2092.9990.8796.3096.36---
Operating Margin-9.61-15.72-65.90-820.53-242.92-21.32---
Net Margin-102.93-14.72-63.16-778.89-240.51-24.25---
Shares Outstanding49.3042.5538.3534.2126.7320.7020.3220.3219.51
Market Capitalization3,640.233,640.232,116.62670.37391.01465.23839.84851.83-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue194.57173.91162.05151.67118.70102.6678.3366.41
Cost of Goods Sold Incl. D&A13.8912.119.4010.938.316.245.214.93
Gross Profit180.68161.80152.66140.74110.3996.4273.1261.48
Selling, General and Administrative Excl. Other212.21181.71158.78148.72124.92118.6199.4085.90
Research and Development44.1931.0122.3518.0416.2815.5914.4116.87
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-31.54-19.91-6.12-7.98-14.53-22.18-26.28-24.42
Interest Expense2.192.162.132.212.272.242.212.31
Unusual Expense630.560.000.000.000.000.000.000.00
Net Income Before Taxes-663.69-15.84-4.62-6.31-12.59-20.34-25.12-23.11
Income Taxes4.642.722.352.060.000.000.000.00
Consolidated Net Income-668.33-18.55-6.97-8.37-12.59-20.34-25.12-23.11
Net Income From Continuing Operations-668.33-18.55-6.97-8.37-12.59-20.34-25.12-23.11
Net Income-668.33-18.55-6.97-8.37-12.59-20.34-25.12-23.11
EPS (Recurring)-4.89-0.43-0.16-0.20-0.30-0.48-0.64-0.60
EPS (Basic, Before Extraordinaries)-14.40-0.43-0.16-0.20-0.30-0.48-0.64-0.60
EPS (Diluted)-14.40-0.43-0.16-0.20-0.30-0.48-0.64-0.60
EBITDA-30.51-18.91-5.68-7.53-14.13-21.73-25.82-23.99
Non-Operating Income (Expense)0.596.233.633.884.214.083.373.62
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense21.5010.509.455.5512.248.236.937.40
Price To Sales Ratio5.354.505.637.766.925.818.6511.67
Gross Margin92.8693.0394.2092.8093.0093.9293.3592.58
Operating Margin-16.21-11.45-3.78-5.26-12.24-21.61-33.55-36.77
Net Margin-343.49-10.67-4.30-5.52-10.60-19.81-32.07-34.80
Shares Outstanding49.3043.2743.0242.5542.4542.2142.0038.35
Market Capitalization3,640.232,707.932,985.413,475.732,508.781,702.002,137.382,116.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments417.83291.38227.44217.03171.81168.1557.972.38
Short Term Receivables87.1148.0617.713.580.090.020.040.00
Inventories4.372.623.110.000.000.000.000.00
Other Current Assets13.4714.657.874.774.042.490.020.00
Total Current Assets522.78356.70256.13225.38175.95170.6658.032.38
Net Property, Plant & Equipment21.752.873.351.531.831.240.280.01
Total Investments and Advances5.875.560.630.480.660.000.000.00
Intangible Assets7.378.333.87----0.00
Deferred Tax Assets4.740.350.73-----
Other Assets4.393.531.510.480.460.080.010.00
Total Assets566.90377.35266.22227.86178.91171.9758.322.39
Short Term Debt Incl. Current Port. of LT Debt0.000.610.400.720.610.280.060.00
Accounts Payable16.3927.7418.155.272.862.240.460.17
Income Tax Payable1.81--0.010.06---
Other Current Liabilities117.5052.2718.399.437.962.870.300.00
Total Current Liabilities135.6980.6136.9415.4311.485.390.820.18
Long Term Debt83.0471.8431.3319.490.580.550.100.00
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Deferred Tax Liabilities4.740.350.73-----
Other Liabilities0.000.000.230.050.110.060.000.00
Total Liabilities223.47152.8169.2434.9612.185.990.920.18
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.0063.403.56
Common Equity343.43224.53196.99192.90166.73165.98-6.00-1.35
Total Shareholders Equity343.43224.53196.99192.90166.73165.9857.402.21
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity343.43224.53196.99192.90166.73165.9857.402.21
Total Liabilities & Stockholders Equity566.90377.35266.22227.86178.91171.9758.322.39
Book Value Per Share8.075.855.767.228.068.17-0.30-0.07
Tangible Book Value Per Share7.905.645.647.228.068.17-0.30-0.07
Full-Time Employees370323244874620--
Price to Book Ratio34.998.913.141.932.795.06-47.78-
Return on Assets-14.07-35.91-55.01-30.53-7.88-23.28-15.39-
Return on Equity-23.39-54.83-69.71-34.53-8.31-24.01-15.67-
Return on Invested Capital-15.57-38.99-59.52-29.23-8.26-16.10-8.12-59.68
Quick Ratio3.824.396.8514.6115.3331.6870.8513.31
Current Ratio3.854.426.9314.6115.3331.6870.8513.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-702.23-66.42-115.55-135.89-62.09-13.83-26.81-4.67-1.32
Depreciation2.911.821.230.880.790.610.250.070.00
Other Funds (Non Cash)699.1537.5127.4617.2213.2215.603.970.440.01
Funds from Operations-0.17-27.09-86.87-117.80-48.082.38-22.60-4.16-1.31
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital50.0714.643.840.31-0.951.371.460.480.13
Cash from Operating Activities49.90-12.45-83.03-117.49-49.033.75-21.14-3.67-1.18
Capital Expenditures-17.46-9.86-6.57-5.50-0.51-0.59-0.46-0.17-0.01
Net Assets From Acquisitions-260.380.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments116.94-32.26-192.63146.11-144.120.000.000.000.00
Purchase of Investments-165.65-394.06-265.63-28.66-149.440.000.000.000.00
Sale Or Maturity of Investments282.59361.8073.00174.775.320.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-160.90-42.12-199.19140.60-144.63-0.59-0.46-0.17-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock134.63143.39115.06120.1874.860.02131.7757.463.56
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.030.000.00
Sale of Common Pref Stock134.63143.39115.06120.1874.860.02131.8057.463.56
Proceedsfrom Stock Options121.76134.77107.65118.6074.28-0.08131.4357.463.56
Issuance or Reduction of Debt, Net0.000.0039.6010.0019.120.000.001.990.00
Change in Long Term Debt0.000.0039.6010.0019.120.000.001.990.00
Issuance of Long Term Debt0.000.0071.4810.0019.120.000.001.990.00
Reduction of Long Term Debt0.000.00-31.880.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities134.63143.39154.66130.1893.990.02131.7759.453.56
Net Change in Cash23.6288.82-127.57153.29-99.673.18110.1855.602.37
Free Cash Flow32.44-22.31-84.59-119.00-49.543.16-21.59-3.85-1.19
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow112.49----146.26---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments309.61449.69388.73417.83401.84381.14
Short Term Receivables102.1198.31117.2187.1174.3460.24
Inventories5.164.384.574.373.843.87
Other Current Assets28.549.6126.7213.4721.7029.17
Total Current Assets445.42561.99537.23522.78501.70474.43
Net Property, Plant & Equipment31.1130.4027.6721.7515.983.41
Total Investments and Advances9.068.685.875.875.565.56
Intangible Assets16.646.887.137.377.617.85
Deferred Tax Assets---4.74--
Other Assets3.263.193.244.393.713.75
Total Assets505.50611.14581.13566.90534.56494.99
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.080.32
Accounts Payable34.6940.1424.1316.3940.6428.07
Income Tax Payable5.672.100.561.81--
Other Current Liabilities186.75133.51118.81117.5076.3361.86
Total Current Liabilities227.11175.75143.51135.69117.0590.25
Long Term Debt88.6788.6688.6883.0482.4372.13
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---4.74--
Other Liabilities85.690.000.000.000.000.00
Total Liabilities401.47264.41232.18223.47199.48162.38
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity104.03346.73348.95343.43335.08332.61
Total Shareholders Equity104.03346.73348.95343.43335.08332.61
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity104.03346.73348.95343.43335.08332.61
Total Liabilities & Stockholders Equity505.50611.14581.13566.90534.56494.99
Book Value Per Share2.118.018.118.077.897.88
Tangible Book Value Per Share1.777.857.957.907.717.69
Full-Time Employees---370--
Price to Book Ratio34.997.768.6910.377.544.97
Return on Assets-135.04-8.40-8.92-14.07-17.82-21.10
Return on Equity-319.84-13.68-13.96-23.39-28.35-31.46
Return on Invested Capital-346.83-4.26-1.59-1.96-3.01-5.03
Quick Ratio1.943.173.713.824.255.21
Current Ratio1.963.203.743.854.295.26

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-668.33-18.55-6.97-8.37-12.59-20.34
Depreciation1.031.000.440.440.460.45
Other Funds (Non Cash)663.9710.1511.3513.6911.056.86
Funds from Operations-3.34-7.414.825.75-1.07-13.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.6668.63-29.4813.5719.33-16.36
Cash from Operating Activities-6.0061.22-24.6519.3318.26-29.39
Capital Expenditures-1.21-4.07-5.82-6.36-1.91-1.00
Net Assets From Acquisitions-260.380.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments72.1041.95-52.7455.63-2.83-50.70
Purchase of Investments0.00-2.40-126.80-36.45-102.33-129.70
Sale Or Maturity of Investments72.1044.3574.0692.0899.5079.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-189.4937.88-58.5649.27-4.74-51.70
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock127.813.301.202.312.561.95
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock127.813.301.202.312.561.95
Proceedsfrom Stock Options120.331.440.000.000.00-0.35
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities127.813.301.202.312.561.95
Net Change in Cash-67.68102.40-82.0170.9216.08-79.14
Free Cash Flow-7.2157.15-30.4712.9716.35-30.39
Price to Free Cash Flow112.4948.77----

Revenue breakdown

License And Collaboration2024: 2.89M
Product2024: 180.06M 2025: 451.36M
United States2024: 182.95M 2025: 451.36M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.00%6.1M46.7M831.57K
2026-10-1512.29%5.7M46.7M843.33K
2026-09-3013.76%6.1M44.1M970.40K
2026-09-1513.89%6.1M44.1M1.01M
2026-08-3114.56%6.0M41.3M942.32K
2026-08-1414.54%6.0M41.2M959.34K
2026-07-3114.61%6.0M41.2M969.58K
2026-07-1514.32%5.8M40.4M921.15K
2026-06-3014.58%5.9M40.4M682.10K
2026-06-1512.37%5.0M40.3M606.48K
2026-05-2912.70%5.1M40.4M597.24K
2026-05-1512.15%4.9M40.4M628.77K
2026-04-3011.95%4.8M40.3M576.42K
2026-04-1511.42%4.6M39.9M558.84K
2026-03-3111.46%4.6M39.9M588.96K
2026-03-1312.58%5.0M39.9M645.78K
2026-02-2713.34%5.3M39.9M627.53K
2026-02-1313.68%5.5M39.9M557.49K
2026-01-3014.84%5.8M39.2M551.16K
2026-01-1513.70%5.4M39.2M540.99K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call45.0029.0032.900.002.8100.000.000.944-0.1860.013
call47.5026.5030.500.002.6340.000.000.939-0.1820.014
call50.0024.1028.2025.622.5320.002.000.934-0.1780.015
call55.0019.0022.800.001.9040.000.000.920-0.1690.018
call60.0014.0018.107.701.6682.000.000.901-0.1570.021
call62.5011.5015.009.001.2222.000.000.889-0.1510.023
call65.009.0013.605.441.4275.000.000.872-0.1430.025
call67.507.0011.500.001.3670.000.000.711-0.4410.041
call70.005.009.000.001.1440.000.000.680-0.3940.043
call72.504.506.605.340.9522.002.000.638-0.3320.045
call75.002.954.804.800.84473.003.000.581-0.2780.047
call77.500.504.905.481.1284.000.000.497-0.3010.048
call80.000.004.903.451.37311.000.000.447-0.3560.047
call82.500.004.901.351.6241.000.000.407-0.4120.046
call85.000.002.002.001.1556.000.000.260-0.2330.039
call87.500.004.901.251.2431.000.000.250-0.2600.038
call90.000.004.902.001.3491190.000.236-0.2750.037
call95.000.004.902.551.5911.000.000.210-0.3010.034
call1000.004.601.951.7844.000.000.194-0.3220.033
call1050.004.900.001.9770.000.000.180-0.3400.031
call1100.004.900.002.1090.000.000.171-0.3570.030
call1150.004.900.742.30510.000.000.162-0.3700.029
call1200.005.000.002.4420.000.000.155-0.3850.028
put45.000.004.900.004.2840.000.00-0.136-0.6090.026
put47.500.004.900.003.9680.000.00-0.148-0.5950.027
put50.000.004.900.002.0180.000.00-0.066-0.1730.015
put55.000.004.900.001.6530.000.00-0.080-0.1630.018
put60.000.004.900.802.58011.000.00-0.224-0.5010.035
put62.500.004.901.602.32726.000.00-0.246-0.4760.037
put65.000.100.802.302.1065.000.00-0.268-0.4520.039
put67.500.004.903.101.8533.000.00-0.299-0.4190.041
put70.000.004.905.151.68239.000.00-0.320-0.3870.043
put72.500.304.905.201.4354.000.00-0.361-0.3250.045
put75.001.554.902.511.19513.001.00-0.417-0.2700.047
put77.502.606.0010.201.0712.000.00-0.512-0.2960.047
put80.004.008.008.701.3121.000.00-0.545-0.3410.048
put82.505.509.900.001.2131.000.00-0.585-0.3760.047
put85.007.1011.9011.801.2621.000.00-0.717-0.2250.041
put87.509.6014.000.001.5210.000.00-0.741-0.2440.039
put90.0011.9016.500.001.6690.000.00-0.758-0.2600.037
put95.0016.6021.400.001.6570.000.00-0.785-0.2880.035
put10021.5026.400.001.8720.000.00-0.804-0.3100.033
put10526.5031.400.002.0670.000.00-0.817-0.3290.032
put11031.5036.400.002.2460.000.00-0.828-0.3450.031
put11536.5041.400.002.4130.000.00-0.837-0.3590.030
put12041.5046.400.002.5680.000.00-0.844-0.3710.029

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-053Initial statement of beneficial ownership of securities2026-11-01SEC
2026-11-05SCHEDULE 13GSEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-138-K/A2026-09-04SEC
2026-10-13S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-10-13S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-108-KCurrent report2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-25144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09004.39M8
2026-080000
2026-070000
2026-06002.45M4
2026-050000
2026-040000
2026-03007.94M24
2026-020000
2026-01001.26M1
2025-12003.12M5
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.96%
Deep Track Capital, LP8.52%
RTW INVESTMENTS, LP7.80%
FMR LLC7.00%
Jupiter Topco LLC6.53%
Paradigm Biocapital Advisors LP6.45%
MORGAN STANLEY4.25%
VANGUARD CAPITAL MANAGEMENT LLC4.17%
JENNISON ASSOCIATES LLC3.87%
TANG CAPITAL MANAGEMENT LLC3.65%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
iShares Russell 2000 ETF2.53%
Fidelity Small Cap Index Fund1.06%
VANGUARD EXTENDED MARKET INDEX FUND1.06%
LORD ABBETT DEVELOPING GROWTH FUND INC0.99%
PGIM Jennison Small Company Fund0.95%
iShares Russell 2000 Growth ETF0.90%
Select Health Care Portfolio0.82%
Janus Henderson Global Life Sciences Fund0.81%
Nomura Small Cap Growth Fund0.80%

OakChart. TARS. Cached 15 minutes.